Platelet transfusion refractoriness
Keywords:
-Abstract
-
Downloads
Download data is not yet available.
References
1. Murphy MF. Managing the platelet refractory patient. ISBT Science Series. 2014;9:234-8.
2. Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26:315-20.
3. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251-6.
4. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10-23.
5. Rebulla P. Formulae for the definition of refractoriness to platelet transfusion. Transfus Med. 1993;3:91-3.
6. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness – practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171:297-305.
7. Daly PA, Schiffer CA, Aisner J, Wiernik PH. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA. 1980;243:435-8.
8. Dunbar NM, Ornstein DL, Dumont LJ. ABO incompatible platelets: risks versus benefit. Curr Opin Hematol. 2012;19:475-9.
9. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Eng J Med. 1997;337:1861-9.
10. Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol. 1997;74:185-9.
11. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang. 1994;66:200-5.
12. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106-14.
13. Lalezari P, Driscoll AM. Ability of thrombocytes to acquire HLA specificity from plasma. Blood. 1982;59:167-70.
14. Datema G, Stein S, Eijsink C, Mulder A, Claas FH, Doxiadis II. HLA-C expression on platelets: studies with an HLA-Cw1-specific human monoclonal antibody. Vox Sang. 2000;79:108-11.
15. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012;79:237-45.
16. Murphy MF, Metcalfe P, Ord J, Lister TA, Waters AH. Disappearance of HLA and platelet-specific antibodies in acute leukemia patients alloimmunized by multiple transfusion. Br J Haematol. 1987;67:255-60.
17. Atlas E, Freedman J, Blanchette V, Kazatchkine M, Semple JW. Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood. 1993;81:538-42.
18. Bang KWA, Speck ER, Blanchette VS, Freedman J, Semple JW. Unique processing pathways within recipient antigen presenting cells determine IgG immune responsiveness against donor platelet MHC antigens. Blood. 2000;95:1735-42.
19. Jackman RP, Lee JH, Pei R, Bolgiano D, Lebedeva M, Slichter SJ, et al. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants. Transfusion. 2016;56:1442-50.
20. EMBL-EBI. Immuno polymorphism database- alloantigen/protein data. [accessed 2020 May 14]. Available from: https://www.ebi.ac.uk/ipd/hpa/table1.html.
21. International Platelet Immunology Nomenclature Committee. [accessed 2020 May 14]. Available from: https://www.versiti.org/hpa
22. Curtis BR, McFarland JG. Human platelet antigens - 2013. Vox Sang. 2014;106:93-102.
23. Tsuno NH, Matsuhashi JL, Nagura Y, Okazaki H, Santoso S. The importance of platelet antigens and antibodies in immune-mediated thrombocytopenia. ISBT Science Series. 2014;9:104-11.
24. Kupatawintu P, Nathalang O, O-Charoen R, Patmasiriwat P. Gene frequencies of the HPA-1 to 6 and Gov human platelet antigens in Thai blood donors. Immunohematology. 2005;21:5-9.
25. Romphruk AV, Akahat J, Srivanichrak P, Puapairoj C, Romphruk A, Leelayuwat C. Genotyping of human platelet antigens in ethnic Northeastern Thais by the polymerase chain reaction-sequence specific primer technique. J Med Assoc Thai. 2000;83:1333-9.
26. Vassallo RR. Recognition and management of antibodies to human platelet antigens in platelet transfusion–refractory patients. Immunohematology. 2009;25:119-24.
27. Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, et al. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Transfus Med. 2018;28:40-6.
28. Srisuddee A, Kupatawintu P, Roekchai C, Inorn K, Phiancharoen S, Nathalang O, et al. A study of platelet antibody detection in patients at the National Blood Centre, Thai Red Cross Society. J Hematol Transfus Med. 2016;26:183-9.
29. Loewenthal R, Rosenberg N, Kalt R, Dardik R, Landau M, Yahalom V, et al. Compound heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia. Transfusion. 2013;53:344-52.
30. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785-91.
31. Hsieh FL, Turner L, Bolla JR, Robinson CV, Lavstsen T, Higgins MK. The structural basis for CD36 binding by the malaria parasite. Nat Commun. 2016;7:12837.
32. Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African American is similar to that of Asians. Transfusion. 1996;36:331-4.
33. Xu X, Liu Y, Hong X, Chen S, Ma K, Lan X, et al. Variants of CD36 gene and their association with CD36 protein expression in platelets. Blood Transfus. 2014;12:557-64.
34. Yanai H, Chiba H, Fujiwara H, Morimoto M, Abe K, Yoshida S, et al. Phenotype-genotype correlation in CD36 deficiency types I and II. Thromb Haemost. 2000;84:436-41.
35. Fujino H, Ohta K, Taniue J, Nagano N, Hino M, Yamane T, et al. Primary refractoriness to platelet transfusion caused by Nak(a) antibody alone. Vox Sang. 2001;81:42-4.
36. Kengkate M, Srisuddee A, Roekchai C, Chinbordee K, Phiancharoen S, Kupatawintu P, et al. The study of CD36 (Naka antigen) phenotype in platelet apheresis donors of the National Blood Centre, Thai Red Cross Society. J Hematol Transfus Med. 2017;27:111-6.
37. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood. 2000;96:1574–81.
38. Schmidt AE, Refaai MA, Coppage M. HLA-mediated platelet refractoriness. Am J Clin Pathol. 2019;151:353-63.
39. Matsuhashi M, Tsuno NH. Laboratory testing for the diagnosis of immune-mediated thrombocytopenia. Ann Blood. 2018;3:41
40. Kuptawintu P, Jitjak N, Saelee S, O-Charoen R, Nathalang O. The incidence of platelet antibody in thrombocytopenic patients. J Hematol Transfus Med. 2000;10:123-7.
41. Vongchan P, Nawarawong W, Linhardt RJ. Modification of solid phase red cell adherence assay for the detection of platelet antibodies in patients with thrombocytopenia. Am J Clin Pathol. 2008;130:455-66.
42. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody – specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70:1722-6.
43. Campbell K, Rishi K, Howkins G, Gilby D, Mushens R, Ghevaert C. et al. A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation. Vox Sang. 2007;93:289-97.
44. Fujiwara K, Shimano K, Tanaka H, Sekine M. Kashiwase K, Uchikawa M, et al. Application of bead array technology to simultaneous detection of human leucocyte antigen and human platelet antigen antibodies. Vox Sang. 2009;96:244-51.
45. Metzner K, Bauer J, Ponzi H, Ujcich A, Curtis BR. Detection and identification of platelet antibodies using a sensitive multiplex assay system–platelet antibody bead array. Transfusion. 2017;57:1724-33.
46. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing luminex binding antibodies—a new tool for prediction of graft failure after heart transplantation. Am J Transplant. 2007;7:2809-15.
47. Hayashi T, Hirayama F. Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping. Blood Transfus. 2015;13:380-90.
48. Curtis BR. Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders. Semin Thromb Hemost. 2008;34:539-48.
49. Davey S, Navarrete C, Brown C. Simultaneous human platelet antigen genotyping and detection of novel single nucleotide polymorphisms by targeted next-generation sequencing. Transfusion. 2017;57:1497-1504.
50. Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, et al. Guidelines for the use of platelet transfusions a British Society for Haematology Guideline. Br J Haematol. 2017;176:365-94.
51. Kopko PM, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune-refractory patients. Transfusion. 2015;55:235-44.
52. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Hematol. 2008;142:348-60.
53. Vassallo RR. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol. 2007;14:655-63.
54. Petz LD, Garratty G, Calhoun L, Clark B, Terasaki PI, Gresens C, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion. 2000;40:1446-56.
55. Zhang N, Santoso S, Aster RH, Curtis BR, Newman PJ. Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies. Blood. 2019;134:e1-e8.
56. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens. 2011;77:525-34.
57. Pai S, Lo S, Tsai SL, Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion. 2010;50:2318-27.
2. Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26:315-20.
3. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251-6.
4. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10-23.
5. Rebulla P. Formulae for the definition of refractoriness to platelet transfusion. Transfus Med. 1993;3:91-3.
6. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness – practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171:297-305.
7. Daly PA, Schiffer CA, Aisner J, Wiernik PH. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA. 1980;243:435-8.
8. Dunbar NM, Ornstein DL, Dumont LJ. ABO incompatible platelets: risks versus benefit. Curr Opin Hematol. 2012;19:475-9.
9. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Eng J Med. 1997;337:1861-9.
10. Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol. 1997;74:185-9.
11. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang. 1994;66:200-5.
12. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106-14.
13. Lalezari P, Driscoll AM. Ability of thrombocytes to acquire HLA specificity from plasma. Blood. 1982;59:167-70.
14. Datema G, Stein S, Eijsink C, Mulder A, Claas FH, Doxiadis II. HLA-C expression on platelets: studies with an HLA-Cw1-specific human monoclonal antibody. Vox Sang. 2000;79:108-11.
15. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012;79:237-45.
16. Murphy MF, Metcalfe P, Ord J, Lister TA, Waters AH. Disappearance of HLA and platelet-specific antibodies in acute leukemia patients alloimmunized by multiple transfusion. Br J Haematol. 1987;67:255-60.
17. Atlas E, Freedman J, Blanchette V, Kazatchkine M, Semple JW. Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood. 1993;81:538-42.
18. Bang KWA, Speck ER, Blanchette VS, Freedman J, Semple JW. Unique processing pathways within recipient antigen presenting cells determine IgG immune responsiveness against donor platelet MHC antigens. Blood. 2000;95:1735-42.
19. Jackman RP, Lee JH, Pei R, Bolgiano D, Lebedeva M, Slichter SJ, et al. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants. Transfusion. 2016;56:1442-50.
20. EMBL-EBI. Immuno polymorphism database- alloantigen/protein data. [accessed 2020 May 14]. Available from: https://www.ebi.ac.uk/ipd/hpa/table1.html.
21. International Platelet Immunology Nomenclature Committee. [accessed 2020 May 14]. Available from: https://www.versiti.org/hpa
22. Curtis BR, McFarland JG. Human platelet antigens - 2013. Vox Sang. 2014;106:93-102.
23. Tsuno NH, Matsuhashi JL, Nagura Y, Okazaki H, Santoso S. The importance of platelet antigens and antibodies in immune-mediated thrombocytopenia. ISBT Science Series. 2014;9:104-11.
24. Kupatawintu P, Nathalang O, O-Charoen R, Patmasiriwat P. Gene frequencies of the HPA-1 to 6 and Gov human platelet antigens in Thai blood donors. Immunohematology. 2005;21:5-9.
25. Romphruk AV, Akahat J, Srivanichrak P, Puapairoj C, Romphruk A, Leelayuwat C. Genotyping of human platelet antigens in ethnic Northeastern Thais by the polymerase chain reaction-sequence specific primer technique. J Med Assoc Thai. 2000;83:1333-9.
26. Vassallo RR. Recognition and management of antibodies to human platelet antigens in platelet transfusion–refractory patients. Immunohematology. 2009;25:119-24.
27. Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, et al. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Transfus Med. 2018;28:40-6.
28. Srisuddee A, Kupatawintu P, Roekchai C, Inorn K, Phiancharoen S, Nathalang O, et al. A study of platelet antibody detection in patients at the National Blood Centre, Thai Red Cross Society. J Hematol Transfus Med. 2016;26:183-9.
29. Loewenthal R, Rosenberg N, Kalt R, Dardik R, Landau M, Yahalom V, et al. Compound heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia. Transfusion. 2013;53:344-52.
30. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785-91.
31. Hsieh FL, Turner L, Bolla JR, Robinson CV, Lavstsen T, Higgins MK. The structural basis for CD36 binding by the malaria parasite. Nat Commun. 2016;7:12837.
32. Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African American is similar to that of Asians. Transfusion. 1996;36:331-4.
33. Xu X, Liu Y, Hong X, Chen S, Ma K, Lan X, et al. Variants of CD36 gene and their association with CD36 protein expression in platelets. Blood Transfus. 2014;12:557-64.
34. Yanai H, Chiba H, Fujiwara H, Morimoto M, Abe K, Yoshida S, et al. Phenotype-genotype correlation in CD36 deficiency types I and II. Thromb Haemost. 2000;84:436-41.
35. Fujino H, Ohta K, Taniue J, Nagano N, Hino M, Yamane T, et al. Primary refractoriness to platelet transfusion caused by Nak(a) antibody alone. Vox Sang. 2001;81:42-4.
36. Kengkate M, Srisuddee A, Roekchai C, Chinbordee K, Phiancharoen S, Kupatawintu P, et al. The study of CD36 (Naka antigen) phenotype in platelet apheresis donors of the National Blood Centre, Thai Red Cross Society. J Hematol Transfus Med. 2017;27:111-6.
37. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood. 2000;96:1574–81.
38. Schmidt AE, Refaai MA, Coppage M. HLA-mediated platelet refractoriness. Am J Clin Pathol. 2019;151:353-63.
39. Matsuhashi M, Tsuno NH. Laboratory testing for the diagnosis of immune-mediated thrombocytopenia. Ann Blood. 2018;3:41
40. Kuptawintu P, Jitjak N, Saelee S, O-Charoen R, Nathalang O. The incidence of platelet antibody in thrombocytopenic patients. J Hematol Transfus Med. 2000;10:123-7.
41. Vongchan P, Nawarawong W, Linhardt RJ. Modification of solid phase red cell adherence assay for the detection of platelet antibodies in patients with thrombocytopenia. Am J Clin Pathol. 2008;130:455-66.
42. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody – specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70:1722-6.
43. Campbell K, Rishi K, Howkins G, Gilby D, Mushens R, Ghevaert C. et al. A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation. Vox Sang. 2007;93:289-97.
44. Fujiwara K, Shimano K, Tanaka H, Sekine M. Kashiwase K, Uchikawa M, et al. Application of bead array technology to simultaneous detection of human leucocyte antigen and human platelet antigen antibodies. Vox Sang. 2009;96:244-51.
45. Metzner K, Bauer J, Ponzi H, Ujcich A, Curtis BR. Detection and identification of platelet antibodies using a sensitive multiplex assay system–platelet antibody bead array. Transfusion. 2017;57:1724-33.
46. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing luminex binding antibodies—a new tool for prediction of graft failure after heart transplantation. Am J Transplant. 2007;7:2809-15.
47. Hayashi T, Hirayama F. Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping. Blood Transfus. 2015;13:380-90.
48. Curtis BR. Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders. Semin Thromb Hemost. 2008;34:539-48.
49. Davey S, Navarrete C, Brown C. Simultaneous human platelet antigen genotyping and detection of novel single nucleotide polymorphisms by targeted next-generation sequencing. Transfusion. 2017;57:1497-1504.
50. Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, et al. Guidelines for the use of platelet transfusions a British Society for Haematology Guideline. Br J Haematol. 2017;176:365-94.
51. Kopko PM, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune-refractory patients. Transfusion. 2015;55:235-44.
52. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Hematol. 2008;142:348-60.
53. Vassallo RR. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol. 2007;14:655-63.
54. Petz LD, Garratty G, Calhoun L, Clark B, Terasaki PI, Gresens C, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion. 2000;40:1446-56.
55. Zhang N, Santoso S, Aster RH, Curtis BR, Newman PJ. Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies. Blood. 2019;134:e1-e8.
56. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens. 2011;77:525-34.
57. Pai S, Lo S, Tsai SL, Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion. 2010;50:2318-27.
Downloads
Published
2020-09-24
Issue
Section
บทความฟื้นวิชา (Literature review)
